Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell L

• 作 者: Eduardo Santiesteban Leslie Pe
• 机 构: CelestinoHerná,ndezRobauHospital,CenterofMolecularImmunology,HermanosAmeijeirasHospital,José
• 出 处: 临床医学国际期刊(英文)
• 发表日期: 2014年14期
• 关键词: NON-SMALL Cell LUNG CANCER CANCER VACCINE SECOND-LINE Treatment Non-Small Cell L

Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The aim of this study was to evaluate safet